Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma is viewed favorably because ronde-cel has already shown strong 3rd-line DLBCL efficacy, including 93% ORR, 76% CR, and 18-month mPFS in the ASH 2025 dataset, while updated safety data in N=64 to N=65 patients suggests no Grade ≥3 CRS with prophylaxis and only 8% Grade ≥3 ICANS. The investment case is further strengthened by a more favorable competitive backdrop after Kite/Gilead’s KITE-753 clinical hold and J&J’s discontinuation of prizlo-cel, leaving Breyanzi as the main benchmark rather than a crowded next-generation field. Beyond LBCL, the newly acquired GCC-targeted LYL273 adds another value driver, and Lyell’s wholly owned LyFE manufacturing center, with capacity for >1,200 doses per year and a 16-day vein-to-site time, supports scalable commercial readiness.

Lyell Immunopharma is facing a fundamentally high-risk profile because its value depends heavily on unproven CAR-T assets that still have no FDA or EMA approvals, while safety concerns remain central after CAR-T class toxicities and LYL273’s observed grade 3 diarrhea, grade 4 colitis, and fatal fungal sepsis. The company also faces meaningful regulatory and execution uncertainty, with LYL273’s clinical updates now expected in 2027 rather than 2H:26 and the End-of-Phase I FDA meeting also pushed to 2027, while competitive pressure is intense in LBCL and mCRC from established and emerging rivals. Financially, it still appears likely to need additional capital to fund trials and potential commercialization, and the $40M upfront plus 1.9M shares paid for LYL273 underscores the expensive, dilution-prone nature of its strategy.